Roche Oral SM Late Entrant Roche (RO7795068) is running two pivotal Phase 3 trials (ENITH-1: obesity without T2D
Noteworthy, a significant reduction in BP, MSNA, fasting insulin and creatinine clearance was found, whereas cardiac and sympathetic baroreflex sensitivity were improved (Lambert et al., 2014)
Boxed warning for Contrave : Contrave has a boxed warning due to the increased risk of suicidal thoughts and behaviors
The View from the Crows Nest In 2024, biopharma and healthcare saw cautious optimism, with GLP-1s maintaining dominance despite rising competition, while AI showed promise but lacked full impact in drug discovery
Brand-Name Costs Wegovy: $1,349 per month without insurance Ozempic: $969 per month without insurance Even with insurance coverage, copays often range from $100 to $300 monthly
Building on this research, Annovis recently investigated whether combining buntanetap with the GLP-1 agonist dulaglutide would produce a synergistic effect in the same animal model